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Late recurrence of breast carcinoma 
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Abstract 
Background: We report a rare case of a patient with a hypopharyngeal metastasis from breast cancer.
Case presentation: Isolated breast cancer metastasis to the hypopharynx has been previously reported in only 
one autopsy case. Herein, we report a 56-year-old woman with metastases to the hypopharynx almost 24 years after 
receiving a mastectomy and chemotherapy to treat primary breast carcinoma. We believe that she is the first patient 
to be treated for metastatic breast carcinoma to the hypopharynx. The hypopharyngeal tumor reduced in size after 
administration of an oral aromatase inhibitor. The patient has remained alive with a preserved larynx for three years.
Conclusions: Breast cancer metastasis to the hypopharynx is an extremely rare event.
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Background
In women, breast cancer is diagnosed in approximately 
23 % of all cancer cases, which is the highest proportion 
amongst all cancer types and accounts for approximately 
7.6 million deaths worldwide each year. Approximately 
90 % of these deaths are due to metastatic dissemination 
of the disease (Cummings et al. 2014). In one study, the 
most common sites of the first metastasis of breast can-
cer were the bone (35 %), lungs (23 %), skin (22 %), and 
regional lymph nodes (16  %) during an average obser-
vation period of 3.6  years (range 0.8–6.4  years) (Kamby 
et al. 1988). The incidence of metastatic carcinoma in the 
hypopharynx is extremely low. To our knowledge, only 
one autopsy case has been previously reported (Nguyen 
and Weitzner 1983).
Here, we report a case of dormant breast carcinoma 
metastasis to the hypopharynx. We also evaluated E-cad-
herin and VEGFR2 expression levels and methylation sta-
tuses in order to help elucidate the mechanism of dormant 
ER-positive breast cancer metastasis in this case.
Case presentation
A 56-year-old woman had undergone a mastectomy 
with axillary lymph node dissection at 32  years of age 
(T2N1M0). She received tamoxifen for 2 years after sur-
gery. When she was 42 years old, she was diagnosed with 
lung metastasis from the breast cancer, and a right upper 
lung lobe resection and lymph node dissection were per-
formed. Images of the invasive ductal breast carcinoma 
that was resected when the patient was 32  years old 
and the lung metastasis from the breast cancer that was 
resected when the patient was 42 years old are shown in 
Fig. 1a and b, respectively.
More than 10 years after the lung resection, when the 
patient was 56 years old, she was referred to our hospi-
tal after complaining of dyspnea on exertion. She had a 
3-month history of weight loss and a left neck mass. On 
hypopharyngoscopy, a tumor lesion was found in the 
left anterior wall of the hypopharynx, and the patient 
experienced bilateral vocal cord paralysis (Fig.  2a). A 
contrast-enhanced computed tomography (CT) scan of 
the neck revealed a 24-mm heterogeneously enhanced 
tumor that extended through the left anterior wall of 
the hypopharynx (Fig.  2b). We performed a tracheos-
tomy, hypopharyngeal biopsy, and lymph node extrac-
tion. Moreover, fluorodeoxyglucose positron emission 
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tomography revealed high-level accumulation in the pri-
mary tumor, with a maximum standardized uptake value 
of 5.6, and metastatic neck lymph nodes. There was no 
evidence of a primary lung tumor or other distant metas-
tases (Fig. 2c).
A pathologist analyzed the hypopharyngeal biopsy 
sample (Fig.  3a, b) and diagnosed the neck lymph node 
lesion as a hypopharyngeal metastasis from breast can-
cer. The biopsy sample was estrogen receptor (ER)-pos-
itive, progesterone receptor (PR)-positive, and human 
epidermal growth factor receptor type 2 (HER2)-negative 
(Fig. 3c–f). The patient completed oral aromatase inhibi-
tor therapy and has remained alive after laryngeal pres-
ervation and hypopharyngeal tumor resection for the 
past 3  years. There was no evidence of any other active 
disease. The patient responded well, but she showed 
no objective improvement in laryngeal nerve function 
with a tracheostomy tube. This patient provided written 
informed consent under a protocol approved by the Insti-
tutional Review Boards at the Hamamatsu University 
School of Medicine.
E‑cadherin, VEGF‑A, and VEGFR2 expression 
and methylation analyses
We sought to determine a mechanism leading to metasta-
sis by focusing on E-cadherin, vascular endothelial growth 
factor A (VEGF-A), and vascular endothelial growth factor 
receptor 2 (VEGFR2). We examined E-cadherin, VEGF-A, 
and VEGFR2 protein expression levels. On immunohis-
tochemical analysis, the neck lymph node lesion strongly 
expressed E-cadherin (Fig.  4a), VEGF-A (Fig.  4b), and 
VEGFR2 (Fig. 4c). Genomic DNA was extracted from the 
neck lymph nodes using the QIAamp DNA FFPE Tissue 
Kit (QIAGEN, Hilden, Germany). Bisulfite modification 
of genomic DNA converts unmethylated cytidine residues 
to uradine residues that are then converted to thymidine 
residues during subsequent polymerase chain reaction 
(PCR) (Misawa et al. 2015). The primers listed in Table 1 
were used to analyze E-cadherin and VEGFR2 methyla-
tion statuses. The PCR products were separated by elec-
trophoresis through a 9 % polyacrylamide gel and stained 
with ethidium bromide. For E-cadherin and VEGFR2, only 
unmethylated alleles were detected (Fig. 4c). Neck lymph 
node tumors without E-cadherin and VEGFR2 promoter 
methylation exhibited relatively robust protein expression 
levels. DNA methylation and mRNA expression data for 
invasive breast carcinomas were collected from MethHC: 
a database of DNA methylation and gene expression 
in human cancer (http://methhc.mbc.nctu.edu.tw/php/
index.php) in April 2016 (Fig. 5) (Huang et al. 2015).
Discussion
Metastatic breast cancer causes symptoms that dif-
fer based on the location of the metastasis (Weng et  al. 
2014). This patient was referred to our hospital after 
complaining of dyspnea upon exertion. The metastatic 
breast cancer was difficult to diagnose from the observa-
tion of the mucosal hypopharyngeal surface. To ascertain 
distant metastatic breast carcinoma, immunohistochem-
istry should be performed to detect specific mark-ers 
(Kamby et al. 1988) (Weng et al. 2014). At least two types 
of markers must be evaluated: markers that are expressed 
similarly in the original and metastatic lesions and mark-
ers that can be used to differentiate between metastatic 
lesions and surrounding components (Zhang et al. 2013).
Approximately 20–40  % of patients with ER-positive 
breast cancer eventually develop recurrences in distant 
organs, and half of these events occur at least 5  years 
after diagnosis of the primary tumor. This phenomenon 
is especially pronounced in patients with ER-positive 
Fig. 1 a The invasive ductal breast carcinoma specimen that was resected when the patient was 32 years old (H&E). b The lung metastasis from 
breast cancer that was resected when the patient was 42 years old (H&E)
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breast cancer, suggesting that E-positive cancer cells 
may remain dormant for a protracted period, despite 
adjuvant therapy (Zhang et  al. 2013). Late recurrence 
is thought to be to the result of cancerous cells becom-
ing activated from a dormant state, in which little or no 
de novo DNA transcription occurs and minimal protein 
translation from RNA occurs only to maintain the veg-
etative functions that sustain cell viability (Meltzer 1990). 
These findings suggest that the presence of certain cel-
lular receptors may correlate with biological behavior of 
tumors, as manifested by differences in response to ther-
apy and metastatic distributions.
Many human metastatic breast cancer lesions express 
membranous E-cadherin, whereas their paired primary 
tumors are E-cadherin-negative (Chao et  al. 2010). 
Although E-cadherin re-expression and accompanying 
morphological changes have been achieved, any sub-
sequent full or partial mesenchymal to epithelial tran-
sition has not been adequately assessed (Chao et  al. 
2012). E-cadherin re-expression due to loss of meth-
ylation suggests a functional mechanism by which the 
microenvironment modulates the mesenchymal to epi-
thelial phenotypic switch (Taylor et  al. 2014; Wendt 
et al. 2011).
Fig. 2 a On a hypopharyngeal fiberscopic image, a tumor was observed in the postcricoid area (a white arrow). b On a contrast-enhanced com-
puted tomography scan of the neck before treatment, an enhanced tumor was observed in the postcricoid area of the hypopharynx (a white arrow). 
c On a fluorodeoxyglucose positron emission tomography scan of the neck before treatment, an enhanced tumor was observed in the hypophar-
ynx (a black arrow) and the left side of the neck (arrowhead)
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VEGF-A and VEGFR2 are often co-expressed in breast 
cancer and potentially affect cellular pathways and the 
expression levels of key proteins that are targeted by 
endocrine therapy, such as ER (Mele et al. 2010). Expres-
sion of tumor-specific VEGFR2 is a predictive marker for 
response to tamoxifen in breast cancer patients (Ryden 
et al. 2005a). Elevated VEGF-A and VEGFR2 expression 
levels are associated with poor prognosis and poor 
response to tamoxifen therapy, suggesting that the com-
bination of anti-hormone treatment with an anti-angi-
ogenic strategy should be tested in clinical trials (Patel 
et al. 2010; Ryden et al. 2005b).
Patients with ER-positive breast cancers generally have 
a more favorable clinical outcomes, better prognoses, 
Fig. 3 Hematoxylin-eosin staining (H&E) and immunohistochemical studies. a Microscopic photos of the hypopharyngeal biopsy specimen (H&E). 
b The hypopharyngeal biopsy sample was diagnosed as metastatic breast carcinoma after positive ER immunostaining. c Microscopic photos of the 
lymph node specimen (H&E). d Positive ER immunostaining. e Positive progesterone receptor immunostaining. f Positive mammaglobin immu-
nostaining
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and better patterns of recurrence. Anti-estrogens, such 
as tamoxifen, and aromatase inhibitors, such as letro-
zole, can effectively control the disease and induce tumor 
responses in a large proportion of patients (Milani et  al. 
2014). For many years, tamoxifen was the most widely 
used first-line hormonal therapy for post-menopausal 
patients with hormone-sensitive advanced or metastatic 
breast cancer. Aromatase inhibitors, which have shown 
superior efficacy in advanced disease when compared 
with tamoxifen, have now largely replaced tamoxifen as 
first-line therapy in postmenopausal women (Riemsma 
et al. 2010).
Conclusions
In conclusion, hypopharyngeal metastasis of breast can-
cer is extremely rare. This case highlights the importance 
of immunohistochemical analysis in hypopharyngeal 
tumor diagnosis. ER, VEGF, and VEGFR2 expression 
levels are used when prescribing aromatase inhibitors 
as adjuvant treatment for postmenopausal patients. 
The patient in this study is currently alive after laryn-
geal preservation and hypopharyngeal tumor resec-
tion  3  years ago. E-cadherin and VEGFR2 expression 
levels and methylation statuses may be used to improve 
Fig. 4 a E-cadherin was expressed in the lymph node specimen. b Positive VEGF-A receptor immunostaining. c Positive VEGFR2 receptor immu-
nostaining. d Electrophoresis of methylation-specific PCR products that were amplified using DNA from the lymph node specimen. The results 
show that only unmethylated alleles of CDH1 and VEGFR2 were detected. M methylated alleles, UnM unmethylated alleles, B water blank






MSP E-cadherin Forward TTAGGTTAGAGGGTTATCGCGT
Reverse TAACTAAAAATTCACCTACCGAC
UMSP E-cadherin Forward TAATTTTAGGTTAGAGGGTTATTGT
Reverse CACAACCAATCAACAACACA
MSP VEGFR2 Forward TCGAGTTTTGGGTATTTCGTTCGGT
Reverse AACGACCCGAATCTCCACGCA
UMSP VEGFR2 Forward TTGAGTTTTGGGTATTTTGTTTGGT
Reverse AACAACCCAAATCTCCACACA
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our understanding of ER-positive breast cancer reactiva-
tion after dormancy. However, these associations should 
be interpreted with caution because we have examined 
only one case.
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